Provider incentives and prescribing behavior in Europe

References

• Department of Health. Improving Prescribing. HMSO, London, UK (1990).
   Google Scholar
• Le Grand J, Mays N, Mulligan J. Learning from the NHS Internal Market: a Review of the Evidence. King's Fund. London, UK (1998).
   Google Scholar
• Chaix-Couturier C, Durand-Zaleski I, Jolly D et al. Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues. Int. J. Qual. Health Care12, 133–142 (2000).
   PubMed Web of Science ®Google Scholar
• Mossialos E, Le Grand J. Health Care and Cost Containment in the European Union. Ashgate, Aldershot, UK (1999).
   Google Scholar
• Lopez-Bastida J, Mossialos E. Pharmaceutical expenditure in Spain: cost and control. Int. J. Health Serv.30, 597–616 (2000).
   PubMedGoogle Scholar
• Donatini A, Rico A. Health Care Systems in Transition: Italy. European Observatory on Health Care Systems, Copenhagen, Denmark (2001).
   Google Scholar
• Majeed A, Evans N, Head P. What can PACT tell us about prescribing in general practice? Br. Med. J.315, 1515–1519 (1997).
   PubMedGoogle Scholar
• Bellingham C. Prescribing: pace of change continues. Pharm. J.273, 91 (2004).
   Google Scholar
• Harris CM, Scrivener G. Fundholders' prescribing costs: the first five years. Br. Med. J.313, 1531–1534 (1996).
   PubMedGoogle Scholar
• Wilson RP, Hatcher J, Barton S et al. General practice fundholders' prescribing savings in one region of the United Kingdom, 1991–1994. Health Pol.42, 29–37 (1997).
   PubMedGoogle Scholar
• Matsaganis M, Glennerster H. The threat of "cream skimming" in the post-reform NHS. J. Health Econ.13, 31–60 (1994).
   PubMed Web of Science ®Google Scholar
• Tobin MD, Packham CJ. Can primary care groups learn how to manage demand from fundholders? A study of fundholders in Nottingham. Br. J. Gen. Prac.49, 291–294 (1999).
   PubMedGoogle Scholar
• Gosden T, Torgerson DJ. The effect of fundholding on prescribing and referral costs: a review of the evidence. Health Pol.40, 103–114 (1997).
   PubMed Web of Science ®Google Scholar
• Carthy P, Harvey I, Brawn R et al. A study of factors associated with costs and variation in prescribing among GPs. Fam. Practice17(1), 36–41 (2000).
   PubMed Web of Science ®Google Scholar
• Audit Commission. A Prescription for Improvement: Towards More Rational Prescribing in General Practice. HMSO, London, UK (1994).
   Google Scholar
• Bateman DN, Campbell M, Donaldson LJ et al. A prescribing incentive scheme for non-fundholding general practices: an observational study. Br. Med. J.313, 535–538 (1996).
   PubMedGoogle Scholar
• Ashworth M, Armstrong D, Colwill S et al. Motivating general practitioners to change their prescribing: the incentive of working together. J. Clin. Pharm. Ther.25, 119–124 (2000).
   PubMedGoogle Scholar
• Ashworth M, Lea R, Gray H et al. How are primary care organizations using financial incentives to influence prescribing? J. Pub. Health26(1), 48–51 (2004).
   PubMedGoogle Scholar
• Mason A, Towse A, Drummond M et al. Influencing Prescribing in Primary Care Led NHS. Office of Health Economics, London, UK (2003).
   Google Scholar
• Ashworth M, Golding S, Shepherd L et al. Prescribing incentive schemes in two NHS regions: cross sectional survey. Commentary: prescribing incentive schemes – more evidence is needed of how they work. Br. Med. J.324, 1187–1188 (2002).
   PubMedGoogle Scholar
• Roland M. Linking physicians' pay to the quality of care – a major experiment in the United Kingdom. N. Engl. J. Med.351(14), 1448–1453 (2004).
   PubMed Web of Science ®Google Scholar
• Walley T, Mrazek M, Mossialos E. Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. Int. J. Health Plan. Management (2005) (In Press).
   PubMedGoogle Scholar
• Delnoij D, Brenner G. Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding? Health Pol.52, 157–169 (2000).
   PubMed Web of Science ®Google Scholar
• Busse R, Howerth C. Cost containment in Germany: twenty years experience. In: Health Care and Cost Containment in European Union. Mossialos E, Le Grand J (Eds). Ashgate, Aldershot, UK (1999).
   Google Scholar
• Busse R. Health Care Systems in Transition: Germany. European Observatory on Health Care Systems, Copenhagen, Denmark (2000).
   Google Scholar
• Junger C, Rathmann W, Gianni C. Prescribing behavior of primary care physicians in diabetes therapy: effect of drug budgeting. Ditsch Med. Wochenschr.125, 103–109 (2000).
   PubMedGoogle Scholar
• Weltermann B, Martin C, Adl S et al. Prescribing practice for β-blockers at patient discharge to ambulatory care. A health care economic evaluation in a cardiology patient sample with special reference to drug budgeting. Gesundheitswesen59, 258–261 (1997).
   PubMedGoogle Scholar
• MMW. Erhebliche Defizite bei der Arzneimittelversorgung. MMW-Fortschritte der Medizin143, 43 (2001).
   Google Scholar
• Schoffski O, Graf von der Schulenburg JM. Unintended effects of a cost-containment policy: results of a natural experiment in Germany. Social Sci. Med.45, 1537–1539 (1997).
   PubMedGoogle Scholar
• Schoffski O. Consequences of implementing a drug budget for office-based physicians in Germany. PharmacoEconomics10(Suppl. 2), 37–47 (1996).
   PubMedGoogle Scholar
• Busse R, Henke K, Schreyogg J. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures. Int. J. Health Plan. Management (2005) (In Press).
   PubMedGoogle Scholar
• Presse-und Informationsamt der Bundersregierung. Sozialpolitische Umschau. Presse-und Informationsamt der Bundersregierung, Berlin, Germany (2002).
   Google Scholar
• Dietrich ES. Arzneimitteldaten; das drama der späten lieferung. DeutschesÄrzteblatt97, A-3321 (2000).
   Google Scholar
• Jacker A. Alternativen zu arzneimittelbudgets. Pharmazeutische Industrie62, 74–143 (2000).
   Google Scholar
• Schwermann T, Greiner W, Schulenburg VD. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany. Value Health6(Suppl. 1), S20–S30 (2003).
   Google Scholar
• Korzilius H. Arzneimittelbudget: die zeit danach. Deutsches Arzteblatt98, A-2844 (2001).
   Google Scholar
• Sperschneider T, Kleinert S. Germany's sick health-care system. Lancet360, 1758 (2002).
   PubMedGoogle Scholar
• Taxis K, Schneeweiss S. Frequency and predictors of drug therapy interruptions after hospital discharge under physician drug budgets in Germany. Int. J. Clin. Pharmacol. Ther.41(2), 77–82 (2002).
   Google Scholar
• Walley T, Murphy M, Codd M et al. Effects of a monetary incentive on primary care prescribing in Ireland: changes in prescribing patterns in one health Board 1990–1995. Pharmacoepidemiol. Drug Safety9, 591–598 (2000).
   PubMedGoogle Scholar
• Comptroller and Auditor General. Prescribing Practices and the Development of General Practitioner Services. Comptroller and Auditor General (John Purcell), Department of Health and Children, Dublin, Ireland (1997).
   Google Scholar
• Durieux P. The Introduction of Regulatory Practice Guidelines in the French Health Care System. Paper Presented at The Conference on European Integration and Health Care Systems: a Challenge for Social Policy, 1–8 (2001).
   Google Scholar
• Durieux P, Gaillac B, Giraudeau B et al. Despite financial penalties, French physicians' knowledge of regulatory practice guidelines is poor. Arch. Fam. Med.9, 414–418 (2000).
   PubMedGoogle Scholar
• Durieux P, Chaix-Couturier C, Durand-Zaleski I et al. From clinical recommendations to mandatory practice: the introduction of regulatory practice guidelines in the French healthcare system. Int. J. Technol. Assess. Health Care16, 969–975 (2000).
   PubMedGoogle Scholar
• Paraponaris A, Verger P, Desquins B et al. Delivering generics without regulatory incentives? Empirical evidence from French general practitioners about willingness to prescribe international non-proprietary names. Health Pol.70, 23–32 (2004).
   PubMed Web of Science ®Google Scholar
• Sandier S, Polton D, Paris V. Health Care Systems in Transition: France. European Observatory on Health Care Systems, Copenhagen, Denmark (2004).
   Google Scholar
• CNAMTS. Les Médicaments Remboursés par le Régime d'Assurance Maladie au Cours du Premier Semestre 1999 et u Premier Semestre 2000 (MEDICAM). CNAMTS, Paris, France (2001).
   Google Scholar
• Mair A. Maßnahmen der ÖGKK zur Eindämmung der Steigerungsraten bei den Medikamentenausgaben. Regional health insurer for Oberösterreich. (2005) (In Press).
   Google Scholar
• Fattore G, Jommi C. The new pharmaceutical policy in Italy. Health Pol.46(1), 21–41 (1998).
   PubMed Web of Science ®Google Scholar
• Grumbach K, Osmond D, Vranizan K et al. Primary care physicians' experience of financial incentives in managed-care systems. N. Engl. J. Med.339, 1516–1521 (1998).
   PubMed Web of Science ®Google Scholar
• Sulmasy DP, Bloche MG, Mitchell JM et al. Physicians' ethical beliefs about cost-control arrangements. Arch. Intern. Med.160, 649–657 (2000).
   PubMed Web of Science ®Google Scholar
• Walley T, Murphy M, Codd M et al. Effects of a monetary incentive on primary care prescribing in Ireland: attitudes and perceptions of health care professionals and patients. Eur. J. Gen. Practice7, 92–98 (2001).
   Google Scholar